SCHEMBL3483216

SCHEMBL3483216

COc1ccc(OC(=S)N(C)C)c(Cl)c1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 2/20 0.48
SLC6A4 P31645 5/20 0.43
HTR2A P28223 4/20 0.43
KCNH2 Q12809 3/20 0.43
ALDH1A1 P00352 5/20 0.41
LMNA P02545 1/20 0.41
HTT P42858 1/20 0.41
RAB9A P51151 1/20 0.41
CA12 O43570 1/20 0.40
CA1 P00915 1/20 0.40
CA2 P00918 1/20 0.40
CA7 P43166 1/20 0.40
CA9 Q16790 1/20 0.40
CA14 Q9ULX7 1/20 0.40
SLC6A2 P23975 1/20 0.40
SLC6A3 Q01959 1/20 0.40
MRGPRX4 Q96LA9 1/20 0.39
HPGD P15428 3/20 0.39
RAD52 P43351 1/20 0.39
CYP2C9 P11712 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3483598 0.81 ALDH1A1 (0.41) L3MBTL1ALDH1A1LMNAHTTRAB9A
SCHEMBL4802368 0.78 ALDH1A1 (0.63) L3MBTL1ALDH1A1LMNAHTTRAB9A
SCHEMBL3611178 0.77 ALDH1A1 (0.42) L3MBTL1ALDH1A1LMNAHTTRAB9A
SCHEMBL9217561 0.76 KDM4E (0.49) ALDH1A1LMNAHTTRAB9AHPGD
SCHEMBL11666230 0.75 L3MBTL1 (0.44) L3MBTL1SLC6A4HTR2AKCNH2ALDH1A1
SCHEMBL4156146 0.75 L3MBTL1 (0.49) L3MBTL1SLC6A4ALDH1A1LMNARAB9A
SCHEMBL28788737 0.75 AR (0.48) L3MBTL1SLC6A4HTR2AKCNH2ALDH1A1
SCHEMBL1534102 0.75 ALDH1A1 (0.48) ALDH1A1HTTRAB9AHPGDPOLB
SCHEMBL12950694 0.75 BACE1 (0.56) ALDH1A1HTTRAB9AMRGPRX4HPGD
SCHEMBL197088 0.74 CA12 (0.62) SLC6A4HTR2AALDH1A1HTTCA12

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2049200-B1 NOVEL INHIBITORS OF BETA-LACTAMASE METHYLGENE INC (CA) 2015-04-29 EP disclosed
US-8440643-B2 Inhibitors of beta-lactamase METHYLGENE INC. (CA) 2013-05-14 US disclosed
US-20100279983-A1 NOVEL INHIBITORS OF BETA-LACTAMASE METHYLGENE INC. 2010-11-04 US disclosed
EP-2049200-A2 NOVEL INHIBITORS OF BETA-LACTAMASE MethylGene Inc. (CA) 2009-04-22 EP disclosed
WO-2008073142-A2 NOVEL INHIBITORS OF BETA-LACTAMASE MERCK & CO., INC. (US) 2008-06-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100279983-A1 NOVEL INHIBITORS OF BETA-LACTAMASE MGAM, MGAM2, PGLS L3MBTL1 1271/4885SLC6A4 2222/4885HTR2A 4379/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.